Judith Bergman
Family · Phoenix, AZNPI 1184617128
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Viiv Healthcare Company at 55.1% of the total. Reporting peaked in 2022 at $9,001 and has fallen 97.8% since, to $200 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $61.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$12K
- Gilead$6K
- Merck$813
- EMD Serono, Inc.$437
- Johnson & Johnson$419
- Theratechnologies Inc.$339
- plus $2K from 17 others
What the payments were for
- Consulting fees$10,21546%
- Travel & lodging$2,67612%
- Food & beverage$9,26442%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 94 | $12,271 |
| Gilead | 147 | $6,488 |
| Merck | 24 | $813 |
| EMD Serono, Inc. | 16 | $437 |
| Johnson & Johnson | 25 | $419 |
| Theratechnologies Inc. | 8 | $339 |
| Novo Nordisk | 8 | $335 |
| AbbVie | 8 | $255 |
| Janssen Scientific Affairs, LLC | 2 | $235 |
| Janssen Products, LP | 3 | $202 |
| Antares Pharma, Inc. | 8 | $151 |
| Napo Pharmaceuticals Inc | 5 | $97 |
| Abbott | 2 | $48 |
| Halozyme Inc | 2 | $39 |
| Pfizer | 2 | $36 |
| Eisai Inc. | 1 | $19 |
| Nalu Medical, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
| Oxford Immunotec USA Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,285 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 376 | $1,596,864 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 96 | $404,947 |
| PrezcobixDarunavir/Cobicistat | 151 | $400,693 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 71 | $378,261 |
| DovatoDolutegravir Sodium/Lamivudine | 108 | $374,842 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 71 | $273,430 |
| DescovyEmtricitabine/Tenofov Alafenam | 95 | $223,302 |
| SerostimSomatropin | 11 | $217,217 |
| TivicayDolutegravir Sodium | 66 | $181,070 |
| Egrifta SvTesamorelin Acetate | 19 | $172,682 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 42 | $155,782 |
| JulucaDolutegravir/Rilpivirine | 35 | $120,797 |
| IsentressRaltegravir Potassium | 36 | $72,018 |
| MounjaroTirzepatide | 27 | $53,558 |
| OzempicSemaglutide | 25 | $43,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Vemlidy | $6,488 | $2,242,507579 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca | $12,271 | $832,491251 claims |
| Johnson & JohnsonPrezcobix | $419 | $400,693151 claims |
| Janssen Products, LPSymtuza | $202 | $378,26171 claims |
| EMD Serono, Inc.Serostim | $437 | $217,21711 claims |
| Theratechnologies Inc.Egrifta Sv | $339 | $172,68219 claims |
| MerckIsentress, Januvia, Isentress Hd, Pifeltro, Belsomra | $813 | $164,16198 claims |
| Novo NordiskOzempic | $335 | $43,32525 claims |
| GSKBreo Ellipta, Incruse Ellipta | $17 | $9,13125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
- Susan HawrylkiwPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.